Sight Sciences Inc
$ 3.91
2.36%
15 Apr - close price
- Market Cap 199,282,000 USD
- Current Price $ 3.91
- High / Low $ 3.96 / 3.82
- Stock P/E N/A
- Book Value 1.20
- EPS -0.74
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.17 %
- ROE -0.51 %
- 52 Week High 9.24
- 52 Week Low 2.40
About
Sight Sciences Inc. (SGHT) is a leading medical technology innovator dedicated to revolutionizing the management of eye diseases, particularly glaucoma, through both surgical and non-surgical solutions. The company boasts a diverse array of advanced products and a solid intellectual property portfolio, strategically positioning it to leverage the growing demand for minimally invasive ophthalmic therapies. As Sight Sciences continues to enhance its distribution capabilities and push the boundaries of eye care technology, it represents a compelling investment opportunity for institutional investors seeking exposure in the evolving healthcare landscape.
Analyst Target Price
$8.34
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-05 | 2025-11-06 | 2025-08-07 | 2025-04-30 | 2025-03-05 | 2024-11-07 | 2024-08-01 | 2024-05-02 | 2024-03-07 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.08 | -0.16 | -0.23 | -0.28 | -0.23 | -0.22 | -0.25 | -0.33 | -0.22 | -0.27 | -0.3 | -0.35 |
| Estimated EPS | -0.1529 | -0.26 | -0.26 | -0.28 | -0.176 | -0.21 | -0.3 | -0.28 | -0.32 | -0.32 | -0.34 | -0.39 |
| Surprise | 0.0729 | 0.1 | 0.03 | 0 | -0.054 | -0.01 | 0.05 | -0.05 | 0.1 | 0.05 | 0.04 | 0.04 |
| Surprise Percentage | 47.6782% | 38.4615% | 11.5385% | 0% | -30.6818% | -4.7619% | 16.6667% | -17.8571% | 31.25% | 15.625% | 11.7647% | 10.2564% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.19 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SGHT
2026-04-15 01:10:07
KCK LTD. significantly reduced its stake in Sight Sciences Inc by selling 2,268,820 shares on March 31, 2026, lowering its holding to 1,438,094 shares or 2.70% of its portfolio. This strategic move, conducted at $3.77 per share, reflects a reassessment of investment amidst Sight Sciences' ongoing market and financial challenges. Despite the reduction, Sight Sciences, valued at $206.302 million with a stock price of $3.82, is considered modestly undervalued and shows growth potential despite profitability challenges.
2026-04-13 19:40:06
The article highlights strong momentum in the interventional glaucoma and dry eye markets, with increasing adoption of OMNI and TearCare technologies. It suggests that continued growth for Sight Sciences, Inc. (SGHT) in 2026 and beyond will be driven by expanding reimbursement, scaling sales forces, and ongoing product innovation. This information is based on an AI-generated summary of Sight Sciences, Inc.'s 25th Annual Needham Virtual Healthcare Conference Audio Transcript from April 13, 2026.
2026-04-12 08:10:24
Sight Sciences has won a $34 million patent infringement ruling against Alcon. The dispute centered on Alcon's glaucoma surgical devices. This judgment marks a significant legal victory for Sight Sciences in the ophthalmology market.
2026-04-10 20:09:28
Sight Sciences, Inc. CFO James Rodberg sold 7,231 shares of company stock for $25,670 to cover tax liabilities from restricted stock unit vesting. Despite a significant year-to-date decline, the stock is up 48% over the past 12 months. This news follows the company's strong Q4 2025 earnings beat and a recent $34 million patent infringement legal victory against Alcon Inc.
2026-04-09 22:09:32
Sight Sciences Chief Legal Officer Jeremy B. Hayden sold 13,761 shares of the company's common stock for approximately $48,851. Following the sale, Hayden still owns 369,770 shares. The stock is currently trading near its Fair Value, and the sale follows positive news for Sight Sciences, including better-than-expected Q4 2025 earnings and a $34 million patent infringement victory against Alcon Inc.
2026-04-09 21:09:32
Sight Sciences, Inc.'s Chief Legal Officer, Jeremy B. Hayden, sold 13,761 shares of common stock at a weighted average price of $3.55 per share on April 6, 2026. This sale was conducted to cover tax obligations arising from the vesting of his restricted stock units (RSUs). Following the transaction, Hayden's total holdings amounted to 369,770 shares, including common stock and additional shares from unvested RSUs.
